Printer Friendly

Articles from The Fly (May 12, 2022)

1-171 out of 171 article(s)
Title Author Type Words
2seventy Bio reports Q1 EPS ($3.20), consensus ($2.05). Financial report 155
4D Molecular reports Q1 EPS (82c), consensus (81c). Financial report 166
Aadi Bioscience reports Q1 EPS (66c), consensus (71c). Financial report 190
Aemetis reports Q1 EPS (54c), consensus (39c). Financial report 170
Aeterna Zentaris provides update on AIM Biologicals development program. 230
Affimed to present preclinical data on cytotoxic activity of AFM28. 230
Affirm extends multi-year partnership with Shopify in U.S. 157
Akouos reports Q1 EPS (78c), consensus (73c). Financial report 167
Algonquin Power increases common dividend 6% to $0.1808 per share. 173
Alimera notes positive predictive value of corticosteroids before Iluvien. 330
Ameresco in supply pact with Powin for 2,500 MWh of BESS. 241
Amprius Technologies to go public via merger with Kensington Capital. 196
Applied DNA Sciences reports Q2 EPS (23c), consensus (33c). Financial report 422
Aptevo Therapeutics reports Q1 EPS ($1.55) vs. ($1.64) last year. Financial report 163
Aptinyx reports Q1 EPS (29c), consensus (30c). Financial report 211
Apyx Medical reports Q1 EPS (17c), consensus (15c). Financial report 190
Aravive reports Q1 EPS (62c), consensus (53c). 154
Arcellx reports Q1 EPS ($1.56), consensus (64c). Financial report 227
Asahi Kasei to start providing carbon footprint data for rubber, elastomers. 216
Assembly Biosciences reports Q1 EPS (48c), consensus (47c). Financial report 168
Athira Pharma Q1 EPS (56c) vs. (25c) last year. Financial report 322
Athira Pharma urges holders to back its director nominees at May 19 AM. 196
Aurora Cannabis raises expense savings target to C$150M-C$170M. 161
Bausch + Lomb release survey findings on macular edema treatment. 289
BD announces U.S. launch of infectious disease molecular diagnostics platform. 227
Bio-Techne and Nonagen Bioscience enter supply agreement for bladder cancer test. 165
Bioceres reports Q3 revenue $60.1M, consensus $44.74M. Financial report 341
Biolase reports Q1 EPS (77c), consensus (68c). Financial report 177
Bionano Genomics reports publication highlighting utility of OGM. 291
BiondVax provides update on NanoAbs program at Biomed conference. Conference news 235
BK Technologies reports Q1 EPS (23c) vs. (5c) last year. Financial report 312
Blend Labs reports Q1 EPS (32c), consensus (19c). Financial report 189
Blue Bird reports Q2 EPS (38c) vs. (36c) last year. Financial report 184
Boxlight reports Q1 EPS (7c), consensus (6c). Financial report 190
Bragg's Wild Streak strengthens game development collaboration with IGT. 211
BRC Inc. reports Q1 EPS ($1.36), consensus (2c). Financial report 222
Brickell Biotech reports Q1 EPS (8c), consensus (6c). Financial report 217
BridgeBio announces license agreement with Bristol-Myers for BBP-398. 199
Brilliant Earth reports Q1 adjusted EPS 5c, consensus 4c. Financial report 209
Brookline bullish on Caribou after 'truly stunning' CB-010 data in r/r B-NHL. 169
Cabaletta Bio reports Q1 EPS (45c), consensus (60c). Financial report 195
Calix teams with Bark Technologies on mitigating 'cyberbullying'. 271
Carbon Streaming announces first biochar carbon stream. 351
Caribou Biosciences announces initial data for CB-010. 307
Cascades reports Q1 adjusted EPS (C$0.15) vs. C$0.29 last year. Financial report 464
Casi Pharmaceuticals reports Q1 EPS (6c), consensus (9c). Financial report 188
Chemomab Therapeutics reports Q1 EPS (2c) vs. (1c) last year. Financial report 255
ChromaDex backs FY22 revenue growth view 15%-20%, consensus $79.36M. 152
Compass reports Q1 EPS (45c), consensus (48c). Financial report 167
Constellation Energy reports Q1 EPS 32c, consensus 70c. Financial report 206
CorMedix announces leadership updates, operational changes. 193
Crescent Point Energy raises quarterly dividend by over 40% to 6.5c per share. 255
Crescent Point Energy reports Q1 adjusted EPS 41c, consensus 25c. Financial report 175
Crescent Point now expects to generate $1.2B-$1.4B of excess cash flow in 2022. 240
Crexendo reports Q1 adjusted EPS 2c, consensus 1c. Financial report 202
Crinetics reports Q1 EPS (73c), consensus (58c). Financial report 166
Cullinan, Taiho Pharmaceutical to jointly develop CLN-081/TAS6417. 236
CymaBay reports Q1 EPS (32c), consensus (31c). Financial report 216
Cyxtera Technologies expands to India via partnership with Sify Technologies. 198
D-Orbit successfully completes fifth ION satellite carrier mission. 156
D-Wave announces availability of Advantage quantum computer. 245
DarioHealth reports Q1 EPS (74c), consensus (96c). Financial report 158
Day One Biopharmaceuticals reports Q1 EPS (48c), consensus (38c). Financial report 176
Digital Realty contracts for 158MW of renewable energy in California and Georgia. 156
Duolingo reports Q1 EPS (31c), consensus (57c). Financial report 155
Dynatronics reports Q3 EPS (9c) vs. (0c) last year. Financial report 179
Dynatronics sees 2022 revenue $44M-$45M. 313
eMagin reports Q1 adjusted EPS (2c) vs (10c) last year. Financial report 162
Energy Action:. 214
Energy Vault increases scope of energy storage project with DG Fuels. 215
ESS Inc. reports Q1 EPS (4c), consensus (13c). Financial report 171
Evelo Biosciences reports Q1 EPS (56c), consensus (58c). Financial report 190
Evelo Biosciences reports Q1 EPS (56c), consensus (58c). Financial report 175
Flora Growth establishes on-the-ground presence in UK and EU. 182
Flux Power reports Q3 EPS (23c), consensus (28c). Financial report 249
FX update: haven demand is boosting the dollar and the yen. 157
Global Blood Therapeutics announces data presentations on Sickle Cell Disease. 503
Global Ship Lease announces participation in carbon capture initiative. 255
Gracell to present clinical data on GC012F in RRMM and B-NHL at EHA2022. 185
Graphite Bio reports Q1 EPS (48c), consensus (39c). Financial report 171
Greenpro Capital, Cryptosx create crypto exchange in Malaysia. 197
Idaho Strategic announces addition of Lemhi Pass REE project in Idaho. 468
Imago BioSciences reports Q1 EPS (49c), consensus (43c). Financial report 248
Ingevity publishes environmental product declaration for Evotherm WMA. 200
iTeos Therapeutics reports Q1 EPS ($1.96)), consensus 79c. Financial report 207
Jacobs/Morrison Energy Services JV secures National Grid projects. 182
Jaguar Mining reports Q1 EPS (8c) vs. 8c last year. Financial report 186
Jasper Therapeutics to initiate registrational studies in MDS and AML in 1Q23. 234
Kinnate Biopharma reports Q1 EPS (61c), consensus (61c). Financial report 184
Knight, Helsinn enter license agreement for Akynzeo, Aloxi. 173
Lava Therapeutics announces IND clearance for LAVA-051. 169
LianBio reports Q1 EPS (26c), consensus (30c). Financial report 172
Lineage Cell Therapeutics reports Q1 EPS (4c), consensus (3c). Financial report 245
MakerBot, Ultimaker enter business combination agreement. 175
Matinas BioPharma reports Q1 adjusted EPS 0c, consensus 0c. Financial report 157
MediWound announces results from US Phase 2 trial of EscharEx. 346
MeiraGTx reports Q1 EPS (70c), consensus (52c). 225
MIND C.T.I. reports Q1 EPS 7c vs 7c last year. Financial report 202
Mindset Pharma progresses plans for trials of MSP-1014. 175
Mogo reports Q1 adj. EBITDA loss of $5.5M vs. loss of $1.1M in year ago quarter. Financial report 159
MoneyLion reports Q1 adj EBITDA loss $24.9M vs. loss of $1.2M in last year's. Financial report 174
MoonLake Immunotherapeutics starts Phase 2 Nanobody Sonelokimab trial. 167
MorphoSys to present new data on Pelabresib and Monjuvi at EHA and ASCO. 191
Motus GI Holdings reports Q1 EPS (9c), consensus (11c). Financial report 230
Muscle Maker reports Q1 EPS (7c) vs. (31c) last year. 432
Mustang Bio reports Q1 EPS (20c) vs. (19c) last year. Financial report 209
Mustang Bio says MB-106 trial selected for oral presentation at EHA2022. 244
Mynaric, Airbus U.S. Space & Defense sign contract fo laser communication demo. 203
NeuBase Therapeutics reports Q1 EPS (30c), consensus (23c). Financial report 228
Newegg Commerce shares insights about Newegg Live. 269
Neximmune reports Q1 EPS (66c), consensus (70c). Financial report 222
NGM Biopharmaceuticals announces initiation of Phase 1/1b study of NGM438. 155
Nice reports Q1 adjusted EPS $1.80, consensus $1.71. Financial report 163
Nkarta reports Q1 EPS (79c), consensus (72c). Financial report 165
Nuvalent reports Q1 EPS (36c), consensus (40c). Financial report 172
Orbit International reports Q1 adjusted EPS 16c vs 54c last year. Financial report 241
Pacira reports preliminary April net product sales for Exparel, iovera of $45.8M. Financial report 263
Pear Therapeutics includes QuickMD in telehealth provider experience initiative. 161
PepsiCo taps Billtrust's ACA solution for hard Mountain Dew distribution. 185
Poseida Therapeutics reports Q1 EPS (93c), consensus (66c). Financial report 186
Precision BioSciences announces grant of inducement awards under Nasdaq rule. 168
Priority Technology to launch solution for construction payment challenges. Conference notes 244
Protara Therapeutics presents results of retrospective analysis of OK-432. Clinical report 301
PureCycle reports 215M pounds of polypropylene under LOI. 204
PureCycle says purification facility in Ironton, Ohio remains on track. 293
Quarterhill reports Q1 EPS C$0.44 vs. (C$0.04) last year. Financial report 245
Quebecor reports Q1 adjusted EPS C$0.54 vs. C$0.52 last year. Financial report 592
Realogy to rebrand as Anywhere Real Estate. 176
Revitalist Lifestyle and Wellness reports April revenue C$480,000. Financial report 300
Rockley Photonics announces $81.5M private placement. 236
Sema4 Holdings reports Q1 EPS (31c), consensus (31c). Financial report 246
Sigilon Therapeutics reports Q1 EPS (43c), consensus (33c). Financial report 166
SilverSun Technologies reports Q1 EPS (1c) vs. 7c last year. Financial report 412
Skye Bioscience signs arrangement agreement with Emerald Health Therapeutics. 324
SkyWater in license pact with Xperi for hybrid bonding technology. 151
Smith-Midland Corp continues to face macro challenges. 154
Smith-Midland Corp reports Q1 EPS (2c) vs. 55c last year. Financial report 391
Snap One raises FY22 revenue view $1.16B-$1.18B from $1.14B-$1.17B. 293
Snap One reports Q1 EPS (3c), consensus 9c. Financial report 194
STMicroelectronics targets FY25-FY27 revenue $20B+. 188
Stratasys says MakerBot to merge with Ultimaker. 253
Taboola reports Q1 EPS 8.5c, consensus 5c. Financial report 169
TCR2 Therapeutics reports Q1 EPS (76c), consensus (74c). Financial report 216
The 1k initial claims uptick to 203k. 193
The April U.S. PPI gains. 188
Theseus Pharmaceuticals reports Q1 EPS (27c), consensus (26c). Financial report 177
Titan Medical reports cash, cash equivalents of $30.1M as of March 31. 231
Treasury Action: bonds retain a strong risk off bid. 171
Treasury Action: risk aversion has seen yields dive globally. 236
Treasury Market Outlook. 204
Treasury Market Summary:. 215
Treasury's $ B 4- and 8-week bill offerings were weak. 166
Treasury's $22 B 30-year bond auction was very well received. 190
TUV SUD supports Microvast in sustainable battery production. 197
Twin Vee PowerCats reports Q1 EPS (17c) vs. 3c last year. Financial report 441
Tyson made 'baseless' claims to keep plants open during COVID, House says. 154
Unicycive Therapeutics reports Q1 EPS (24c) vs (11c) last year. Financial report 189
Utz Brands raises FY22 revenue growth view to 10%-13% from 7%-10%. 337
Vallon Pharmaceuticals reports additional data from SEAL study of ADAIR. 459
Ventyx Biosciences reports Q1 EPS (45c), consensus (52c). Financial report 154
Veru reports Q2 EPS (18c), consensus (15c). Financial report 206
Vigil Neuroscience on track to report VGL101 Phase 1 data in 2H. 199
VYNE Therapeutics reports adjusted Q1 EPS (14c) vs (18c) last year. Financial report 160
Wave Life Sciences reports Q1 EPS (62c), consensus (55c). Financial report 203
WestRock publishes 2021 sustainability report. 285
WM Technology launches payments in Ontario. 211
Wolfe downgrades credit card issuers on 80% probability of recession. 221
Xebec Adsorption reports Q1 EPS (C$0.12) vs. (C$0.07) last year. Financial report 171
Zealand Pharma sees FY22 net operating expenses DKK $1B plus or minus 10%. 209
Zevia reports Q1 EPS (30c), consensus (15c). Financial report 174
Zoom Video enters agreement to acquire Solvvy. 169

Terms of use | Privacy policy | Copyright © 2025 Farlex, Inc. | Feedback | For webmasters |